The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma (FL)

Reviewer: Christopher Dolinsky, MD
University of Pennsylvania School of Medicine
Ultima Vez Modificado: 4 de junio del 2006

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

No Adverse Effect of Statins Seen on Lymphoma Outcomes

Nov 26, 2015

Statin use not found to adversely affect outcomes in patients treated with rituximab

Drug Improves Survival in Follicular Lymphoma Patients

Nov 26, 2015

Rituximab maintenance effective in patients with relapsed or refractory disease

Bortezomib Combo Effective in Advanced Follicular Lymphoma

Aug 3, 2011

Bortezomib, bendamustine, rituximab combo active for patients with relapsed follicular lymphoma